Custom service
Cyclic Peptide PPI Inhibitor Development
Develop cyclic peptide inhibitors of protein–protein interactions
Cyclic Peptide PPI Inhibitor Development supports programmes that develop cyclic peptide inhibitors of protein–protein interactions. In a typical engagement we plan the interface-motif extraction route first, confirm compatibility with constrained hotspot presentation, and release inhibitor lead with potency and selectivity data on a 8–14 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep interface-motif extraction as the primary option and hold constrained hotspot presentation in reserve, so that scale-up never depends on an unproven step.
Flat or allosteric PPI interfaces
Hotspot-mimicking macrocycles
PPIs without a defined structural starting point
Cycles whose ring size is known to be geometrically uncloseable
Cyclic products are released against connectivity, not mass alone. MS/MS fragmentation confirms the ring closure, and where multiple topologies are possible the target isomer is isolated and its ratio reported. Protease-stability data are available as an add-on.
Service Highlights
- Interface-motif extraction as the default route, with constrained hotspot presentation held as a proven fallback
- Cell-free and cell-based potency testing worked into the design where the application requires it
- Cyclization strategy (head-to-tail, disulfide, lactam, thioether) chosen from a feasibility screen, not fixed by habit
- Analytical confirmation of every intermediate before the final release
- Cyclic/linear and topological isomers separated and reported, with the target isomer identified by MS/MS
- Inhibitor lead with potency and selectivity data delivered with a complete conjugation or synthesis certificate
How the work runs
Precursor design
Linear precursor, cyclization sites and protecting strategy are designed around the Cyclic Peptide PPI Inhibitor Development ring size.
Linear assembly
The precursor chain is assembled with Fmoc chemistry and interface-motif extraction where relevant.
Cyclization
Ring closure is executed by constrained hotspot presentation under screened dilution and activation conditions.
Isomer separation
RP-HPLC resolves cyclic/linear and topological isomers; the target isomer is collected.
Characterization
Connectivity, purity and identity are confirmed by MS/MS and HPLC against the specification.
Release
Inhibitor lead with potency and selectivity data is documented and released after QC sign-off.
Specifications & timeline
- Turnaround
- 8–14 weeks
- Typical scale
- 1 – 200 mg cyclic peptide
- Chemistry options
- interface-motif extraction; constrained hotspot presentation; cell-free and cell-based potency testing
- Deliverable
- Inhibitor lead with potency and selectivity data
- QC package
- HPLC purity, MS/MS connectivity proof, isomer ratio, DMSO solubility
- Shipping
- Ambient with desiccant; blue ice for sensitive motifs
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.